At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Charlotte Allerton, Pfizer's head of medicine design, said: "The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. "We are looking forward to potentially ...

Pfizer targets $4 billion in operational savings ... molecular profiles (a trend increasingly favored in precision medicine). In short, the pipeline diversity here enables near-term commercial ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

Many dog owners have already heard about the FDA warning and seen the articles on the terrible side effects experienced by ...